At an R&D event hosted by the company in Kendall Square today, Alloy Therapeutics' CEO Errik Anderson talks the latest in science regarding bispecifics, TCR mimics, genetic medicines, and more

blonca9
Mar 25
1 min read

He described the discovery work that Alloy does with its client partners, and highlighted emerging areas of science. Plus, the importance of good murine models, and his take on Chinese competition.

Recent Posts

See All

Swiss Biotech Day: Zurich based LimmaTech Biologics is developing vaccines against antimicrobial resistant pathogens

Swiss Biotech Day: Basel based Nouscom presented data at AACR last week on its cancer vaccine that is meant to lower the risk of Lynch Syndrome carriers from having future cancers

Swiss Biotech Day: Molecular Partners' CEO and Swiss Biotech Association president Patrick Amstutz shares his take on biotech and previews what to expect from his U.S. listed company in 2025

At an R&D event hosted by the company in Kendall Square today, Alloy Therapeutics' CEO Errik Anderson talks the latest in science regarding bispecifics, TCR mimics, genetic medicines, and more

Recent Posts

Join the BiotechTV mailing list

Follow BiotechTV

Sponsors

Sponsor Spotlight